Psychiatric Annals


The Dexamethasone Suppression Test in Psychiatric Disorders

Anthony J Rothschild, MD


Introduction of the DST led to greater interest among psychiatric researchers in the hypothalamic-pituitary-adrenal (HPA) axis.


Introduction of the DST led to greater interest among psychiatric researchers in the hypothalamic-pituitary-adrenal (HPA) axis.

The dexamethasone suppression test (DST) has been one of the most studied biological tests in clinical psychiatry. As has happened with many other new ideas and technologies in the history of science, the DST was first openly embraced by psychiatrists after its standardization and introduction for use in clinical psychiatry in 198 1.1 After wide use and further study in the 1980s, the DST went through a negativistic period in which many clinicians and researchers argued that the DST had little value as a biological test in clinical psychiatry. However, the introduction of the DST led to greater interest among psychiatric researchers in the hypothalamic-pituitary-adrenal (HPA) axis; from the major physiological regulator corticotropin-releasing factor (see Musselman and Nemeroff, this issue2) to the effects of elevated Cortisol levels on outcome and treatment3,4 (see Murphy and Wolkowitz, this issue5).

The purpose of this paper is to review the current knowledge on the use of the DST in a variety of clinical situations. Current controversies and issues remaining for future research will also be discussed.


The most widely employed procedure for administering the DST is as follows: 1.0 mg of dexamethasone, a potent, long-acting synthetic steroid, is taken at 11:00 PM. On the day after the administration of dexamethasone, blood samples for determination of plasma Cortisol concentration are most commonly drawn at 8:00 AM, 4:00 PM, and 11:00 PM. For convenience, often only an afternoon sample is obtained from outpatients, but this does result in a modest loss of test sensitivity.6 A number of medical conditions, including severe weight loss and use of alcohol and certain other medications, can produce false positive results.1,6-7 Although not always clinically possible, ideally patients should be drug-free, physically healthy, and physiologically stable to ensure unambiguous interpretation of DST results.6


The criterion level to define normal plasma concentrations of Cortisol under the test conditions described above is commonly set at 5µg/ dl.1 The cutoff was developed with the modified Murphy competitive protein-binding (CPB) techniques.8 Rubin and colleagues9 have suggested a cutoff of 3.5 µg/dl when using the more specific radioimmunoassay (RIA) technique, while others6 have argued that the utility of the DST in the clinical setting would be enhanced by using a cutoff of 7 µg/dl. It also remains unclear whether the Cortisol abnormality (as measured by the DST) is perhaps better viewed as a spectrum of Cortisol levels rather than a binary, all-or-none, nonsuppression versus suppression classification.


There is now abundant evidence for hyperactivity of the HPA axis in endogenous or melancholic depression.1,6 The sensitivity of the DST (rate of a positive outcome, or nonsuppression of Cortisol) in major depression is about 40% to 50% but it is higher (about 60% to 70%) in very severe, especially psychotic, affective disorders, including major depression with psychotic as well as melancholic features, mania, and schizoaffective disorder.6

The specificity of the DST (the chance of a negative finding when the person tested is free of the condition under study) has been reported to be over 90%1,10-15 with most studies of the DST (involving hundreds of subjects using 1.0 mg of dexamethasone) reporting rates of cortisol nonsuppression in normal controls of approximately 5% to 10%. 16 Since a physician is seldom interested in distinguishing a patient with affective disorder from a normal person, a more important question is the specificity of the DST among patients with other psychiatric or medical illnesses that might be confused with major depression. As the comparison groups have expanded to other diseases, the specificity of the DST (as is the case with all diagnostic tests) has decreased.

The rate of nonsuppression of Cortisol following dexamethasone administration in depressed patients (test sensitivity) is dependent on many technical, physiologic, and clinical factors.16 These include, but are not limited to, dose of dexamethasone used, time of sampling of Cortisol, criteria for nonsuppression, Cortisol sampling methodology, nonspecific stress factors (e.g., hospitalization, medical illnesses), effects of treatment with and withdrawal from psychotropic or other medications, changes in diet and weight, and age.16


One of the most replicable findings in the DST literature is the high rate of DST nonsuppression and markedly elevated postdexamethasone Cortisol levels in patients with psychotic major depression (PMD).11-17-26 For example, our group reported on a study of 88 patients treated at McLean Hospital and 31 healthy control subjects using the DST to identify subtypes of depression.24 A review of the case histories indicated that those patients with major depression and very high plasma Cortisol levels (15 µg/dl or more at 4:00 PM) had a propensity for exhibiting mood-congruent psychotic features (e.g., nihilistic delusions) at the time of study. For example, of the nine patients with major depression who had plasma cortisol levels of 15 µg/dl or more, seven showed psychotic features; and all six with plasma cortisol levels of 17 µg/dl at 4:00 PM or more were psychotic. In contrast, of the remaining 36 patients with major depression whose plasma cortisol levels were less than 15 µg/dl, only seven showed psychotic features (χp 2 = 11.4, df= l,p<.001).24 In this study the frequency of nonsuppression (10 of 14, or 71.4%) was higher in the PMD patients than in the nonpsychotic patients with major depression (18 of 31, or 58. 1%).24

We then compared these psychotically depressed patients with a group of schizophrenic patients to ascertain whether the high postdexamethasone Cortisol levels in the patients with psychotic depression reflected a nonspecific effect due to psychosis.21 Eight of the 14 psychotic patients with major depressive illness had a postdexamethasone 4:00 PM Cortisol level >14 µg/dl. In contrast, none of the psychotic schizophrenic patients had a postdexamethasone 4:00 PM Cortisol level >14 µg/dl.21

The mean postdexamethasone Cortisol levels for the unipolar psychotic depressed patients (13.5 ±8.1 µg/dl) was significantly higher than for psychotic schizophrenic patients (2.4 ± 2.8 µg/dl, p<.05).21 Thus, the high Cortisol levels seen in our patients with unipolar psychotic depression was not due to the psychosis per se, but rather to the presence of psychosis in the context of an affective disorder. Given the high rate of DST nonsuppression in PMD and the lower rates of DST nonsuppression in schizophrenia (see below), the DST may be of clinical utility in the differential diagnosis of PMD from schizophrenia; a differential diagnosis that is often difficult, particularly in a young person.


Studies of the DST in major depression have demonstrated an association between the frequency and degree of dysregulation and increasing age. DST abnormalities in major depression that are associated with increased age include a greater proportion of DST nonsuppressors and increased postdexamethasone Cortisol levels.27"30 Most,28,31"33 but not all,34,35 studies carried out in normal subjects have failed to show an age effect on Cortisol levels after dexamethasone administration. In one study,36 over 90% of normal elderly controls demonstrated suppression on the DST.

The interpretation of nonsuppression on the DST in the geriatric population is complicated by the occurrence of DST abnormalities in Alzheimer's disease,37"39 in multiinfarct dementia,40,41 and by false positives due to unstable physical illnesses that accompany aging, presumably as the direct effect of the illnesses or because of the medications taken by the patients.1,42

A recent study43 of physically healthy and cognitively intact elderly patients with major depression demonstrated that treatment is associated with DST normalization. In this sample of 30 subjects, 60% were nonsuppressors at baseline compared with 17% after intensive treatment. A strong correlation was identified between clinical improvement and decreases in afternoon Cortisol levels.43 The authors argued that there are advantages in using Cortisol as a continuous rather than a categorical measure in assessing the relationship between reversal of depression and DST results in the geriatric population.43


Several studies have investigated the rate of nonsuppression on the DST in dysthymic disorder and borderline personality disorder. Generally, the rate of DST nonsuppression is less than in major depression and similar to what is observed in normal control subjects. For example, in a metaanalysis of 10 studies that used DSM-III criteria comparing DST results in dysthymic disorder, major depression, and other psychiatric disorders in adults,44 the rate of DST nonsuppression was significantly different between patients with dysthymic disorder and those with major depression but not between dysthymic disorder and normal controls.

A review of studies of the DST in borderline personality disorder (BPD) indicated that the majority of studies had low rates of DST nonsuppression.45 Most of the BPD nonsuppressors were depressed, and the rates of nonsuppression in the group that had coexisting BPD and major depressive disorder had nonsuppression rates lower than the published rates of nonsuppression for patients with major depressive disorder alone.45 In general, nondepressed BPD patients were suppressors on the DST.

These studies are consistent with an earlier report by our group that investigated the rates of DST nonsuppression in patients with dysthymic disorder and BPD.24 We reported a rate of DST nonsuppression in the dysthymic disorder/borderline personality disorder group of 16% compared with a rate of DST nonsuppression of 61% in the major depression group. We also found that the mean (±SD) 4:00 PM postdexamethasone Cortisol level for patients with major depression (8.8 ±6.7 µg/dl) was significantly higher than that seen in the dysthymic disorder/borderline personality disorder group (2.9 ± 1.0 ug/dl, p<.05). We did not observe any significant differences between the dysthymic disorder/borderline personality group and the control group on mean (±SD) 4:00 PM postdexamethasone Cortisol levels.


Studies of the DST in schizophrenia have yielded rates of nonsuppression ranging from 0% to 73%.46 Higher rates of DST nonsuppression in schizophrenia have been associated with depressive symptomatology,47,48 negative symptoms,4-49-61 and the nonparanoid subtype.52

Reviews of the DST literature in patients with schizophrenia suggest that variances in DST results may be due to the phase of the illness and the medication status of the patient when the test is performed.4 Several groups have observed4,51,53-56 a reduction in rates of DST nonsuppression in patients with schizophrenia after three to four weeks of neuroleptic treatment. Furthermore, rates of DST nonsuppression are higher in drug-free schizophrenic patients than in medicated patients.4 Although antipsychotic medication regimens are believed to have no effect on the DST,1 other groups7,57 have suggested that withdrawal of neuroleptics/anticholinergics may produce DST nonsuppression lasting up to 21 days.

While further studies are needed to examine the frequency of nonsuppression in patients with schizophrenia, it does appear that the rate of nonsuppression is greater than in normal controls, but not as high as the rate seen in affective disorders.


In general, outpatients with panic disorder are more likely than normal controls, but less likely than patients with major depression, to exhibit dexamethasone nonsuppression, a phenomenon that does not simply reflect coexisting depression.58 In a study using multiple DST testing over a two-month period, Coryell and colleagues58 reported that 18 of 44 (40.9%) panic disorder patients were nonsuppressors on at least one of three DST tests compared with only five of 35 (14.3%) controls (p = 0.006).

Most studies of the DST in panic disorder patients have generally not been designed to address the issue of possible differences between agoraphobic and nonagoraphobic subjects. One study59 reported that panic disorder patients with agoraphobia had higher postdexamethasone serum Cortisol and a higher rate of nonsuppression on the DST than panic disorder patients without agoraphobia or normal controls. DST nonsuppression in panic disorder has been associated with a more persistent and chronically disabling condition.60


Varying rates of nonsuppression on the DST have been reported in obsessivecompulsive disorder (OCD). Several studies have reported low rates of nonsuppression61-63 while others have reported higher rates of nonsuppression.64"67 Insel and colleagues68 reported that inpatients with OCD were much more likely to be nonsuppressors than were outpatients, suggesting that severity might be an important factor. One study63 has suggested that depressive symptoms are associated with higher postdexamethasone Cortisol values in OCD patients, but not all studies agree.62-65,66


Data from DST studies of posttraumatic stress disorder (PTSD) patients have yielded inconclusive results. Four studies6972 have reported normal suppression of Cortisol in nondepressed PTSD patients given the standard 1 mg DST. In PTSD patients who also met criteria for major depression, two studies69,70 reported a nonsuppression pattern on the DST in some patients, and two other studies71,72 showed normal suppression in this subgroup. More recently, Yehuda and colleagues73 have suggested that PTSD patients have enhanced negative feedback sensitivity of the HPA axis because they exhibit an exaggerated suppression response to low doses of dexamethasone. These results are also consistent with previous reports that PTSD patients show low mean basal 24-hour urinary Cortisol excretion74,75 and a higher than normal number of lymphocyte glucocorticoid receptors.76

These recent studies suggest abnormalities in HPA axis activity in PTSD patients, which is the opposite of what is seen in major depression, raising interesting questions for future research. For example, would there be an HPA axis abnormality (and of what type) in patients who concurrently suffer from major depression and PTSD or major depression with psychotic features and PTSD? In particular, there are clinical situations in which the specific diagnosis of the patient is difficult to ascertain. For example, there are patients who suffer from psychotic depression and have a history of abuse or trauma. Are these PTSD patients who exhibit psychotic symptoms or are they patients with major depression with psychotic features and who have a history of trauma? The low-dose DST may be a potentially useful clinical and experimental tool for distinguishing what is primarily a PTSD disorder from major depression with psychotic features.


HPA axis hyperactivity has been reported in patients suffering from anorexia nervosa.77"79 However, since hypercortisolemia occurs with protein-calorie malnutrition80 and since weight loss of greater than 20% of ideal body weight has been found to cause falsepositive DST results,1,12 the weight loss alone may be responsible for some of the observed abnormalities. Walsh and colleagues79 have suggested that some patients with anorexia nervosa exhibit hypercortisolemia that cannot be accounted for solely by weight loss; however, the interpretation of DST results in patients with anorexia nervosa remains difficult.

Several studies have reported nonsuppression on the DST in patients with bulimia.81'83 In one study82 nonsuppressors were more likely to report a family history of treatment for depression in first-degree relatives; however, in two studies82,83 there were no differences between suppressors and nonsuppressors with regard to severity of depression.

Several studies have compared patients with bulimia to normal controls and other psychiatric control groups.84,85,87,88 Hudson and colleagues84 observed that 47% of their bulimic outpatients had DST nonsuppression compared with 9% of normal age-matched controls. They reported no correlation between depression severity and postdexamethasone Cortisol.

Musisi and Garfinkel85 found only a 20% incidence of DST nonsuppression in a largely outpatient bulimic sample compared with 75% of melancholic depressed patients and 10% of normal controls. The low rate of nonsuppression in this study may be due to the inclusion of less severely ill bulimic patients.86

Kiriike and colleagues87 reported an abnormal DST in 63% of bulimic patients compared with 11% of normal controls. In this study most of the suppressors, as well as nonsuppressors, were "clinically depressed" and there was no correlation between Cortisol levels on the DST and the Hamilton Rating Scale for Depression (HRDS).

Finally, Levy and Dixon88 found that 100% of their eight bulimic inpatients were DST nonsuppressors compared with none of eight inpatients with nonendogenous major depression. None of the bulimic patients had concurrent endogenous depression and all were less severely depressed than the major depression comparison group.

Although the significance of nonsuppression on the DST in bulimia is unclear, the finding has been used along with data from phenomenological studies, family history studies, and treatment response studies to suggest that bulimia may be related to affective disorders.84


The DST has been studied extensively in children and adolescents. In a review of 29 studies of the DST in children and adolescents,89 the sensitivity of the DST appeared to be higher among children than among adolescents, higher in subjects from inpatient settings than in outpatient settings, and more specific in adolescent samples. Few differences were observed in rates of nonsuppression for different psychiatric conditions.89 Questions still remain as to the appropriate amount of dexamethasone that should be given when the DST is administered to children and adolescents.


The bioavailability of dexamethasone may be a factor influencing DST results. Postdexamethasone Cortisol values show a significant inverse relationship with plasma dexamethasone concentrations,90"96 and patients with major depression who are DST suppressors have higher plasma dexamethasone concentrations than DST nonsuppressors.97,98 One study has suggested that DST nonsuppressors have a significantly shorter half-life of dexamethasone than DST suppressors, suggesting that DST nonsuppressors may have accelerated metabolism of dexamethasone rather than decreased absorption.99

Another study100 found that clinical response in depressed patients receiving ECT was associated with increased plasma dexamethasone levels, whereas changes in Cortisol levels were independent of clinical outcome. This study raises the intriguing question as to whether clinical recovery is associated with altered bioavailability of dexamethasone. While the preponderance of the evidence suggests that the simultaneous measurement of serum dexamethasone and Cortisol values is helpful to interpret DST results,101 the relationship of plasma dexamethasone levels to clinical outcome99100 suggests that there may be abnormalities in the metabolism and/or bioavailability of dexamethasone itself in depressed patients.


Prolonged elevation of Cortisol levels in depressed patients, as evidenced by failure to convert to normal suppression on the DST, even after an apparently adequate initial clinical response to treatment, has been reported in many studies to be a warning of increased risk for relapse,6,102-107 although not all studies agree.108

Our group recently completed a study3 on the relationships between one-year Cortisol measures and outcome at one year in depressed patients. We observed significant correlations between measures of Cortisol activity (DST, urinary free Cortisol [UFC]) at one year and measures of social and occupational functioning at one year. Patients with UFC values greater than 100 µg/24 hours at one year had significantly poorer functioning as measured by the Social Adjustment Scale - Self Report (SAS-SR)109 total score at one year, than did patients with UFC values less than 100 µg/24 hours. A similar relationship was observed between DST nonsuppressor status at one year and poorer social and occupational functioning at one year.3

The relationship between higher Cortisol levels at one year and poor overall functioning at one year was observed in both psychotic and nonpsychotic depressed patients and appeared even stronger statistically when degree of depression (as measured by total HRDS score) was partialled out. We have hypothesized that the association between higher levels of cortisol at one year and poorer social/occupational functioning is secondary to subtle cognitive deficits caused by the higher Cortisol levels seen in depressed patients.3 Our hypothesis is based on observations that increased HPA axis activity in depressed patients is associated with larger ventricle-to-brain ratios (VBRs)110112 and cognitive disturbances.111,113-119 These studies suggest possible associations among cognitive disturbances, Cortisol hypersecretion, and enlarged ventricles.

Similar observations of relationships between Cortisol and outcome have been reported in patients with schizophrenia. Tandon and colleagues4 reported that persistent DST nonsuppression in schizophrenic patients was associated with greater negative symptom severity at four weeks and poorer outcome at one year. Conversely, conversion of DST nonsuppression at baseline to normal suppression after four weeks of neuroleptic treatment was associated with significantly greater improvement in both negative symptoms and global severity at four weeks. This observation is consistent with previous reports by the same group51 and others.55 Analogous to observations by our group in patients with depression,111 persistent DST nonsuppression in the schizophrenic patients was associated with greater VBRs (although not statistically significant because of the small sample size, ? = 6) and poorer one-year outcome.4

Further studies using larger samples and standardized treatments are needed and are in progress to explore, in a systematic way, the relationships among increased HPA activity, cognition, brain scan abnormalities, and social and occupational functioning in patients with depression and schizophrenia.


The DST, as one of the first laboratory tests introduced in psychiatry, represents an important milestone in the history of psychiatry. As has been reviewed in this paper, the rate of nonsuppression of Cortisol following dexamethasone administration is dependent on diagnosis as well as many technical and physiologic factors. Although the use of the DST in the clinical setting has decreased, the test may have utility in certain situations such as the differentiation of major depression with psychotic features (high nonsuppression rate) from schizophrenia (low nonsuppression rate), a diagnosis that can be clinically difficult, particularly in a young person with a first episode of psychosis.

Attempts to correlate abnormalities observed on administration of the DST with specific psychiatric disorders (with the exception of psychotic depression) has met with limited success. However, it is important to remember that diagnostic classification systems undergo frequent update and revision. If results on measurements of HPA axis activity do not precisely match up with our current diagnostic criteria, it does not necessarily mean that the biological test does not have validity. In the meantime, we are left with the observation that many psychiatric patients have abnormalities on measurements of HPA activity. By further exploring the reasons for and consequences of HPA axis hyperactivity, we hope to learn more about the pathophysiology and treatment of these disorders.


1. Carroll BJ, Feinberg M, Greden JF, et al. A specific laboratory test for the diagnosis of melancholia: standardization, validation, and clinical utility. Arch Gen Psychiatry. 1981; 38:15-22.

2. Musselman D, Nemeroff CB. The role of corticotropinreleasing factor in the pathophysiology of psychiatric disorders. Psychiatric Annals. 1993; 23:676-681.

3. Rothschild AJ, Samson JA, Bond TC, Luciana MM, Schildkraut JJ, Schatzberg AF. Hypothalamicpituitary-adrenal axis activity and one-year outcome in depression. Biol Psychiatry. 1993; 34:392-400.

4. Tandon R, Mazzara C, DeQuardo J, et al. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol Psychiatry'- 1991; 29:953-964.

5. Murphy BEP, Wolkowitz OM. The pathophysiologic significance of hyperadrenocorticism: antiglucocorticoid strategies. Psychiatric Annals. 1993; 23:682-690.

6. APA Task Force on Laboratory Tests in Psychiatry. The dexamethasone suppression test: an overview of its current status in psychiatry. Am J Psychiatry. 1987; 144:1253-1262.

7. Kraus RF, Graf P, Brown M. Drugs and the DST: need for a reappraisal. Am J Psychiatry. 1988; 145:666-674.

8. Murphy BEP. Clinical evaluation of urinary Cortisol determination by competitive protein-binding radioassay. J Clin Endocrinol Metab. 1968; 28:343-348.

9. Rubin BT, Poland RE, Lesser IM, Winston RA, Blodgett ALN. Neuroendocrine aspects of primary endogenous depression, I: Cortisol secretory dynamics in patients and matcbed controls. Arch Gen Psychiatry. 1987; 44:328-336,

10. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression, I: limbic system-adrenocortical dysfunction. ArcA Gen Psyckiatry. 1976; 33:1039-1044.

11. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression, II: discrimination of depressed from nondelusional patients. Arch Gen Psyckiatry. 1976; 33:1051-1058.

12. Schlesser MA, Winokur G, Sherman BM. Hypothalamic-pituitary-adrenal axis activity in depressive illness: its relationship to classification. Arch Gen airy. 1980; 37:737-743.

13. Brown WA, Johnston R, Mayfield D. The 24-hour dexamethasone suppression test in a clinical setting: relationship to diagnosis, symptoms, response to treatment. Am J Psychiatry. 1979; 136:543-547.

14. Nuller JL, Ostroumova MN. Resistance to inhibiting effect of dexamethasone in patients with endogenous depression. Acta Psychiatr Scand. 1980; 61:169-177.

15. Rush AJ, Giles DE, Roffwarg HP, Parker CR. Sleep EEG and dexamethasone suppression test findings in outpatients with unipolar major depressive disorders. Biol Psychiatry. 1982; 17:327-341.

16. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psyckiatry. 1985; 42:1193-1204.

17. Carroll BJ, Greden JF, Feinberg M, et al. Neuroendocrine dysfunction in genetic subtypes of primary unipolar depression. Psychiatry Res. 1980; 2:251-258.

18. Coryell W, Gaffney G, Burkhardt PE. The dexamethasone suppression test and familial subtypes of depression - a naturalistic replication. Biol Psychiatry. 1982; 17:33-40.

19. Asnis GM, Halbreich U, Nathan RS, et al. The dexamethasone suppression test in depressive illness: clinical correlates. Psychoneuroendocrinology. 1982; 7:295-301.

20. Mendlewicz J, Charles G, Franckson JM. The dexamethasone suppression test in affective disorder: relationship to clinical and genetic subgroups. Br J Psychiatry. 1982; 141:464-470.

21. Rothschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. Br. J Psychiatry. 1982; 141:471-474.

22. Rudorfer MV, Hwu H-G, Clayton PJ. Dexamethasone suppression test in primary depression: significance of family history and psychosis. Biol Psychiatry. 1982; 17:41-48.

23. Evans DL, Burnett G, Nemeroff CB. The dexamethasone suppression test in the clinical setting. Am J Psychiatry. 1983; 140:586-589.

24. Schatzberg AF, Rothschild AJ, Stahl JB, et al. The dexamethasone suppression test: identification of subtypes of depression. Am J Psychiatry. 1983; 140:88-91.

25. Caroff S, Winokur A, Rieger W, Schweizer E, Amsterdam J. Response to dexamethasone in psychotic depresssion. Psychiatry Bes. 1983;8:59-64.

26. Rihmer Z1 Arato M, Szadoczky E, et al. The dexamethasone suppression test in psychotic versus nonpsychotic endogenous depression. Br J Psychiatry. 1984; 145:508-511.

27. Sachar EJ1 Asnis G, Halbreich U, Nathan RS, Halpern R. Recent studies in the neuroendocrinology of major depressive disorder. Psychiatr Clin North Am. 1980; 3:313-326.

28. Stokes PE, Stoll PM, Koslow SH1 et al. Pretreatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. Arch Gen Psychiatry. 1984; 41:257-267.

29. Davis KL, Davis BM, Mathe AA, et al. Age and the dexamethasone suppression test in depression. Am J Psychiatry. 1984; 141:872-874.

30. Greden JF, Flegel P, Haskett R, et al. Age effects in serial hypothalamic-pituitary-adrenal monitoring. Psychoneuroendocrinology. 1986; 11:195-204.

31. Tourigny-Rivard M, Roskind M, Rivard D. The dexamethasone suppression test in an elderly population. Biol Psychiatry. 1981; 16:1177-1184.

32. Lewis DA, Pfohl B, Schlechte J1 Coryell W. Influence of age on the Cortisol response to dexamethasone. Psychiatry Res. 1984;13:213-220.

33. Georgotas A, McCue RE, Kim OM, et al, Dexamethasone suppression in dementia, depression, and normal aging. Am J Psychiatry. 1986; 143:452-456.

34. Oxenkrug GF, Pomara N, Mclntyre IM, Branconnier RJ, Stanley M, Gershon S. Aging and Cortisol resistance to suppression by dexamethasone: a positive correlation. Psychiatry Res. 1983; 10:125-130.

35. Weiner MF1 Davis BM, Mohs RC, Davis KL. Influence of age and relative weight on Cortisol suppression in normal subjects. Am J Psychiatry. 1987; 144:646-649.

36. Zimmermann M, Coryell W. The dexamethasone suppression test in healthy controls. Psychoneuroendocrinology. 1987; 12:245-251.

37. Raskind MR, Peskind E, Rivard MF, Veith R, Barnes R. Dexamethasone suppression test and Cortisol Orcadian rhythm in primary degenerative dementia. Am J Psychiatry. 1982; 139:1468-1471.

38. Alexopoulos GS1 Young RC, Haycox JA, Shamoian CA, Blass JP. Dexamethasone suppression test in depression with reversible dementia. Psychiatric Res. 1985; 16:277-285.

39. Greenwald BS, Mathe AA, Mohs RC, Levy MI, Johns CA, Davis KL. Cortisol and Alzheimer's disease, II: dexamethasone suppression, dementia severity, and affective symptoms. Am J Psychiatry. 1986; 143:442-446.

40. McKeith IG. Clinical use of the DST in a psychogeriatric population. Br J Psychiatry. 1984; 145:389-393.

41. Charles GA, LeFevre A, Minel J, Rush AJ. Suppression of Cortisol following dexamethasone in demented patients. Psychiatry Res. 1986; 17:173-182.

42. Magni G, Schifano F, DeLeo D, DeDominicis MG, Garbin A1 Zangaglia O The dexamethasone suppression test in depressed and non-depressed geriatric medical inpatients. Acta Psychiatr Scand. 1986; 73:511-514.

43. Meyers BS, Alpert S, Gabriele M, Kakuma T, Kalayam B, Alexopoulos GS. State specificity of DST abnormalities in geriatric depression. Biol Psychiatry. 1993; 34:108-114.

44. Howland RH, Thase ME. Biological studies of dysthymia. Biol Psychiatry. 1991; 30:283-304.

45. Lahmeyer HW1 Reynolds CF, Kupfer DJ, King R. Biological markers in borderline personality disorder: a review. J Clin Psychiatry. 1989; 50:217-225.

46. Yeragani VK. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can J Psychiatry. 1990; 35:128-132.

47. Munro JG1 Hardiker TM, Leonard DP. The dexamethasone suppression test in residual schizophrenia with depression. Am J Psychiatry. 1984; 141:250-252.

48. Sawyer J, Jeffries JJ. The dexamethasone suppression test in schizophrenia. J Clin Psychiatry. 1984; 45:399-402.

49. Coppen A, Abou-Saleh M, Milln P, Metcalfe M1 Harwood J, Bailey J. Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry. 1983; 142:498-504.

50. Shima S, Kitamura T, Takahashi Y, Asai M. Dexamethasone suppression test and negative symptoms of schizophrenics. Keio J Med. 1986; 35:203-207.

51. Tandon R1 Silk KR, Greden JF, et al. Positive and negative symptoms in schizophrenia and the dexamethasone suppression test. Biol Psychiatry. 1989; 25:788-792.

52. Banki CM, Arato M, Rihmer Z. Neuroendocrine differences among subtypes of schizophrenic disorder. Neuropsychobiobgy. 1984; 11:174-177.

53. Herz MI, Fava GA, Molnar G, Edwards L. The dexamethasone suppression test in newly hospitalized schizophrenic patients. Am J Psychiatry. 1985; 142:127-129.

54. Moller HJ, Kissling W, Bettermann P. The dexamethasone suppression test in depressive and schizophrenic patients under controlled treatment conditions. Eur Arch Psychiatry Neurol Sci. 1986; 235:363-268.

55. Holsboer-Trachsler E, Buoi C, Wiedemann K, Holsboer F. Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels. Acta Psychiatr Scand. 1987; 75:608-613.

56. Wik G, Wiesel FA, Eneroth P, Sedvall G, Astrom G. Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment. Acta Psychiatr Scand. 1986; 74:161-167.

57. Devanand DP, Pandurangi AK, Dewan MJ. False positive dexamethasone test results related to antipsychotic drug withdrawal: case report. J Clin Psychiatry. 1984; 45:275-276.

58. Coryell W, Noyes R Jr, Schlechte J. The significance of HPA axis disturbance in panic disorder. Biol Psychiatry. 1989; 215:989-1002.

59. Westberg P1 Modigh K, Lisjö P, Eriksson E. Higher postdexamethasone serum Cortisol levels in agoraphobia than in nonagoraphobia panic disorder patients. Biol Psychiatry. 1991; 30:247-256.

60. Coryell W, Noyes R Jr, Reich J. The prognostic significance of HPA axis disturbance in panic disorder: a three-year follow-up. Biol Psychiatry. 1991; 29:96-102.

61. Coryell WH, Black DW, Kelly MW, Noyes R Jr. HPA axis disturbance in obsessive-compulsive disorder. Psychiatry Res. 1989;30:243-251.

62. Lieberman JA, Kane JM, Sarantakos S, et al. Dexamethasone suppression tests in patients with obsessive-compulsive disorder. Am J Psychiatry. 1985;747751.

63. Jenike MA, Baer L, Brotman AW, Goff DC, Minichiello WE, Regan NJ. Obsessive-compulsive disorder, depression, and the dexamethasone suppression test. J Clin Psychopharmacol. 1987; 7:182-184.

64. Asberg M, Thoren P, Bertilsson L. Clomipramine treatment of obsessive disorder: biochemical and clinical aspects. Psychopharmacol Bull. 1982; 18:13-21.

65. Cameron OG, Kerber K, Curtis GC. Obsessive-compulsive disorder and the DST. Psychiatry Res. 1986; 19:329-330.

66. Cottraux JA, Bouvard M, Claustrat B . Juenet C. Abnormal dexamethasone suppression test in primary obsessive-compulsive patients: a confirmatory report. Psychiatry Res. 1984; 13:157-165.

67. Perse T, Greist J, Jefferson J. Rosenfeld R, Dar R. Fluvoxamine treatment of obsessive-compulsive disorder. Am J Psychiatry. 1987; 144:1543-1548.

68. Insel TR, Mueller EA, GiIUn JC, Siever LJ, Murphy DL. Tricyclic response and obsessive-compulsive disorder. Prog Neuropsyckopharmacol Biol Psychiatry. 1985; 9:25-31.

69. Kudler H, Davidson J, Meador K, Lipper S, Ely T. The DST and post-traumatic stress disorder. Am J Psychiatry. 1987; 144:1068-1071.

70. Olivera AA, Fero D. Affective disorders, DST, and treatment in PTSD patients: clinical observations. Journal of Traumatic Stress. 1990; 3:407-414.

71. Halbreich U, Olympia J, Carson S, Glogowski J, Yeh CM, Axelrod S, Desu MM. Hypothalamo-pituitary-adrenal activity in endogenously depressed post-traumatic stress disorder patients. Psychoneuroendocrinology. 1989; 14:365-370.

72. Kosten TR, Wahby V, Giller E Jr, Mason J. The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in post-traumatic stress disorder. Biol Psychiatry. 1990; 28:657-664.

73. Yehuda R, South wick SM, Krystal JH, Bremner D, Chamey DS, Mason JW. Enhanced suppression of Cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry. 1993; 150:83-86.

74. Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L. Urinary free Cortisol levels in post-traumatic stress disorder patients. J Nerv Ment Dis. 1986; 174:145-159.

75. Yehuda R, Southwick SM, Nussbaum G, Giller EL, Mason JW. Low urinary Cortisol excretion in PTSD. J Nerv Ment Dis. 1990; 178:366-369.

76. Yehuda R, Lowy MT, Southwick SM, Shaffer D, Giller EL Jr. Lymphocyte glucocorticoid receptor number in posttraumatic stress disorder. Am J Psychiatry. 1991; 148:499-504.

77. Walsh BT, Katz JL, Levin J, et al. Adrenal activity in anorexia nervosa. Psychosom Med. 1978; 40:499-506.

78. Gemer RH, Gwirtsman HE. Abnormalities of dexamethasone suppression test and urinary MHPG in anorexia nervosa. Am J Psychiatry. 1981; 138:650-653.

79. Walsh BT, Katz JL, Levin J, et al. The production rate of Cortisol declines during recovery from anorexia nervosa. J Clin Endocrinol Metab. 1981; 53:203-205.

80. Smith SR, Bledsoe T, Chhetri MK Cortisol metabolism and the pituitary adrenal axis in adults with proteincalorie malnutrition. J Clin Endocrinol Metab. 1975; 40:43-52.

81. Gwirtsman HE, Roy-Byrne P, Yager J, Gerner RH. Neuroendocrine abnormalities in bulimia. Am J Psychiatry. 1983; 140:559-563.

82. Mitchell JE, PyIe RL, Hatsukami D, Boutacoff LI. The dexamethasone suppression test in patients with bulimia. J Clin Psychiatry. 1984; 45:508-511.

83. Lindy DC, Walsh BT, Roose SR, Gladis M, Glassraan AH. The dexamethasone suppression test in bulimia. Am J Psychiatry. 1985; 142:1375-1376.

84. Hudson JI, Pope HG, Jonas JM, Laffer PS, Hudson MS, Melby JC. Hypothalamic-pituitary-adrenal-axis hyperactivity in bulimia. Psychiatry Res. 1983; 8:111-117.

85. Musisi S, Garfinkel P. Comparative dexamethasone suppression test measurements in bulimia, depression and normal controls. Am J Psychiatry. 1985; 30:190-194.

86. Levy AB. Neuroendocrine profile in bulimia nervosa. Biol Psychiatry. 1989;25:98-109.

87. Kiriike N, Nishiwaki S, Izumiya Y, Kawakita Y. Dexamethasone suppression test in bulimia. Biol Psychiatry. 1986; 21:325-328.

88. Levy AB, Dixon KN. DST in bulimia without endogenous depression. Biol Psychiatry. 1987; 22:783-786.

89. Dahl RE, Kaufman J, Ryan ND, et al. The dexamethasone suppression test in children and adolescents: a review and a controlled study. Biol Psychiatry. 1992; 32:109-126.

90. Baumgartner A, Haack DV, Vecesei P. Serial dexamethasone suppression tests in psychiatric illness, III: the influence of intervening variables. Psychiatry Res. 1986; 18:45-64.

91. Arana GW, Reichlin S, Workman R, Haaser R, Shader RI. The dexamethasone suppression index: enhancement of DST diagnostic utility for depression by expressing serum Cortisol as a function of serum dexamethasone. Am J Psychiatry. 1988; 145:707-711.

92. Arana GW, Workman RJ, Baldessarini RJ. Association between low plasma levels of dexamethasone and elevated levels of Cortisol in psychiatric patients given dexamethasone. Am J Psychiatry. 1984; 141:1619-1620.

93. Carson SW, Halbreich U. Effect of treatment on plasma Cortisol and dexamethasone. Biol Psychiatry. 1987; 22:213-216.

94. Poland RE, Rubin RT, Lesser IM, Lane LA, Hart PJ. Neuroendocrine aspects of primary endogenous depression, II: serum dexamethasone concentrations and hypothalamic-pituitary-adrenal cortical activity as determinants of the dexamethasone suppression test response. Arch Gen Psychiatry. 1987; 44:790-795.

95. Walsh BT, Lo ES, Cooper T, et al. Dexamethasone suppression test and plasma dexamethasone levels in bulimia. Arch Gen Psychiatry. 1987; 44:797-800.

96. Ritchie JC, Belkin BM, Krishnan KRR, Nemeroff CB, Carroll BJ. Plasma dexamethasone concentrations and the dexamethasone suppression test. Biol Psychiatry. 1990;27:159-173.

97. Carson SW, Halbreich U, Yeh CM, Asnis G, Goldstein S. Cortisol suppression per nanogram per milliliter of plasma dexamethasone in depressive and normal subjects. Biol Psychiatry. 1988; 24:569-577.

98. Holsboer F, Wiedemann K, Boll E. Shortened dexamethasone half-life in depressed dexamethasone nonsuppressors. Arch Gen Psychiatry. 1986; 43:813-815.

99. Holsboer F, Wiedemann K, Gerken A. Boll E. The plasma dexamethasone variable in depression: testretest studies and early biophase kinetics. Psyckiatry Res. 1986; 17:97-103.

100. Devanand DP, Sackeim HA1 Lo ES1 et al. Serial dexamethasone suppression tests and plasma dexamethasone levels: effects of clinical response to electroconvulsive therapy in major depression. Arch Gen Psychiatry. 1991; 48:525-533.

101. Lowy MT1 Meltzer HY. Dexamethasone bioavailability: implications for DST research. Biol Psyckiatry. 1987; 22:373-385.

102. Greden JF1 Albala AA1 Haskett RF1 et al. Normalization of dexamethasone suppression test: a laboratory index of recovery from endogenous depression. Biol Psyckiatry. 1980; 15:449-458.

103. Rothschild AJ, Schatzberg AF Fluctuating Cortisol levels in a patient with melancholia. Am J Psychiatry. 1982; 139:129-130.

104. Yerevanian BI, Olafasdottier H1 Milanese E1 et al. Normalization of the dexamethasone suppression test at discharge from hospital: its prognostic value. J Affective Disord. 1983; 5:191-197.

105. Nemeroff CB, Evans DL. Correlation between the dexamethasone suppression test in depressed patients and clinical response. Am. J Psychiatry. 1984; 141:247-249.

106. Targum SD. Persistent neuroendocrine dysregulation in major depressive disorder: a marker for early relapse. Biol Psyckiatry. 1984; 19:305-318.

107. Baldessarini RJ, Arana GW. Does the dexamethasone suppression test have clinical utility in psychiatry? J Clin Psychiatry. 1985; 46(2, part 2):25-29.

108. Coryell W, Zimmerman M. The dexamethasone suppression test and ECT outcome: a six-month follow-up. Biol Psychiatry. 1983; 18:21-27.

109. Weissman MM, Prusoff BA1 Thompson WD. Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis. 1978; 166:317-326.

110. Kellner CH1 Rubinow DR1 Gold PW, Post RM. Relationship of Cortisol hypersecretion to brain CT scan alternations in depressed patients. Psychiatry Res. 1983; 8:191-197.

111. Rothschild AJ, Benes F, Hebben N, et al. Relationships between brain CT scan findings and Cortisol in psychotic and nonpsychotic depressed patients. Biol Psychiatry. 1989; 26:565-575.

112. Rao VP, Krishnan KRR, GoIi V, et al. Neuroanatomical changes and hypothalamic-pituitaryadrenal axis abnormalities. Biol Psychiatry. 1989; 26:729-732.

113. Reus VI. Pituitary-adrenal disinhibition as the independent variable in the assessment of behavioral symptoms. Biol Psychiatry. 1982; 17:317-325.

114. Rubinow DR1 Post RM1 Savard R, Gold PW. Cortisol hypersecretion and cognitive impairment in depression. Arch Gen Psychiatry. 1984; 41:279-283.

115. Wolkowitz OM, Reus VL Weingartner H, et al. Cognitive effects of corticosteroids. Am J Psychiatry. 1990; 147:1297-1303.

116. Brown WA, Quails CB. Pituitary-adrenal disinhibition in depression: marker of a subtype with characteristic clinical features and response to treatment? Psychiatry Res. 1981; 4:115-128.

117. Demeter E, Rihmer Z, Arato M1 Frecska E. Association performance and the DST. Psyckiatry Res. 1986; 18:289-290. Letter.

118. Winokur G, Black DW1 Nasrallah A. DST nonsuppressor status; relationship to specific aspects of the depressive syndrome. Biol Psychiatry. 1987; 22:360-368.

119. Sikes CR, Stokes PE1 Lasley BJ. Cognitive sequelae of hypothalamic-pituitary-adrenal (HPAl dysregulation in depression (abstract). Biol Psychiatry. 1989, 25(7A):148A-149A.


Sign up to receive

Journal E-contents